Avian transgenesis via site-directed integration

描述(由申请人提供)：这个第二阶段的SBIR项目描述了一种新的方法来创造转基因家禽，这种家禽将在它们的鸡蛋中产生生物制药蛋白。鸡能够以相对较低的成本在鸡蛋中产生大量蛋白质。我们试图利用这种能力来合成大量所需的药用蛋白质，例如人源化的单抗。 转基因鸡的效率非常低，特别是具有大量转基因的鸡。我们建议通过使用整合促进酶来克服这一障碍，这种酶能够高效地重组特定的DMA序列。 在这个项目的第二阶段，整合促进酶将被用于将编码药用蛋白的转基因插入到鸡的基因组中，并由蛋清特异性启动子驱动。这项新技术将加快创造能够生产药物的鸡，从而促进药物开发，加强临床试验，并降低药物成本。

DESCRIPTION (provided by applicant): This Phase II SBIR project describes a novel method to create transgenic poultry that will produce biopharmaceutical proteins in their eggs. Chickens are able to produce large amounts of protein in their eggs at relatively low cost. We seek to harness this capability to synthesize pharmaceutical proteins, such as humanized monoclonal antibodies, that are needed in large amounts. The efficiency of transgenesis in chickens, particularly with large transgenes, is exceedingly low. We propose here to overcome this hurdle by the use of integration-promoting enzymes which are able to recombine specific DMA sequences with a high efficiency. In Phase II of this project, the integration-promoting enzymes will be used to insert transgenes encoding pharmaceutical proteins, and driven by egg white specific promoters, into the genome of chickens. This novel technology will expedite the creation of chickens that can produce Pharmaceuticals, thereby facilitating drug development, enhancing clinical trials and lowering the cost of Pharmaceuticals.